



<TO BE PRINTED ON LOCAL HOSPITAL HEADED PAPER>

ELEVA↑E

INFORMED CONSENT FORM – TUMOUR SAMPLE SCREENING

Study Title: An open label phase II trial of temozolomide prior to nivolumab in MGMT deficient, advanced oesophagogastric cancer

Researcher: Dr Elizabeth Smyth

ERGO Ref: 61191

REC: 21/EE/0017

IRAS: 282284

*Please
initial each
box*

1. I confirm that I have read and understand the Tumour Sample Screening patient information sheet dated **[Insert here]** for the transfer of my tumour sample to the Laboratories of Cambridge University. I have had the opportunity to ask questions and these have been answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving a reason and without my medical care or legal rights being affected.
3. I understand that relevant sections of my medical records may be looked at by the individuals from the Southampton Clinical Trials Unit (SCTU), the Sponsor or their delegates, from Regulatory Authorities, or from the NHS Trust where it is relevant to the transfer and storage of my tumour block. I give permission for these individuals to have access to my records.
4. I give my permission for a sample of my tumour, previously obtained for diagnostic purposes, to be sent to the laboratories of Cambridge University in order to determine where a MGMT deficiency is present.

